Showing 1581-1590 of 1635 results for "".
- Konan Medical USA Acquires objectiveFIELD Objective Perimeterhttps://modernod.com/news/konan-medical-usa-acquires-objectivefield-objective-perimeter/2479795/Konan Medical USA has acquired objectiveFIELD, an FDA-cleared device designed to assess the human visual field in an objective and non-contact manner. The device was acquired from the Australian National University (ANU), includes novel features licensed from Seeing Machine
- Neurolens Appoints Davis Corley Chief Executive Officerhttps://modernod.com/news/neurolens-appoints-davis-corley-chief-executive-officer/2479848/Neurolens announced that its board of directors has named Davis Corley chief executive officer (CEO). Mr. Corley was a co-founder of neurolens in 2012 and has served as president since 2014, a role that he will continue. “Since day one, Davis has led the dev
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- Allegro Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEOhttps://modernod.com/news/allegro-prepares-to-take-lead-compound-risuteganib-to-phase-3-appoints-new-ceo/2479926/Allegro Ophthalmics announced that its board of directors has named Hampar Karageozian to the position of Executive Chairman and has appointed Vicken Karageozian, MD, to the position of President and Chief Executive O
- Mount Sinai Researchers Discover How to Restore Vision Using Retinal Stem Cellshttps://modernod.com/news/mount-sinai-researchers-discover-how-to-restore-vision-using-retinal-stem-cells/2479939/Researchers at Mount Sinai have successfully restored vision in mice through activating retinal stem cells, something that has never been done before. Their study, published in the August 15 online issue of Nature, could transform treatment for patients with retinal degenerative diseases
- Family Income, Ethnicity, and Health Literacy May Affect Children’s Vision, Eye Care Accesshttps://modernod.com/news/family-income-ethnicity-and-health-literacy-may-affect-childrens-vision-eye-care-access/2479982/August for many children in the United States is the beginning of a brand new school year. According to the recent report from the National Center for Children’s Vision and Eye H
- U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Dealhttps://modernod.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a
- Bausch Health CEO: No Plans to Divest Bausch + Lombhttps://modernod.com/news/valeant-now-officially-bausch-health-companies-begins-trading-as-bhc/2480016/Valeant Pharmaceuticals International completed its name change to Bausch Health Companies. In an interview with Eyewire News to discuss the name change and direction of Bausch + Lomb, Bausch Health Chairman and CEO Joseph Papa said there are no plans to divest the eye care unit. “B
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe
- Some AMD Patients May Not Respond to Intravitreal Aflibercepthttps://modernod.com/news/some-amd-patients-may-not-respond-to-intravitreal-aflibercept/2480030/Although intravitreal aflibercept is effective in the great majority of treatment-naive cases of neovascular age-related macular degeneration (AMD), the drug may not work for a small subgroup of patients with choroidal vascular hyperpermeability, Japanese researchers say, according to a